Novo nordisk shares plunge as obesity drug trails eli lilly's zepbound

Novo nordisk's cagrisema falls short in weight loss trial

Shares of Novo Nordisk plummeted as much as 11% on the Copenhagen Stock Exchange after the company announced that its next-generation obesity injection, CagriSema, demonstrated less weight loss than its rival, Eli Lilly’stirzepatida (marketed as Zepbound). This development represents a significant setback for Novo Nordisk's efforts to maintain its dominance in the rapidly growing weight loss market and raises concerns about CagriSema’s potential market impact.

Key findings from the clinical trial

According to a statement released by Novo Nordisk on Monday, participants treated with a standard dose of CagriSema achieved a 20.2% weight loss after 84 weeks, compared to 23.6% with Lilly's tirzepatida. This difference in efficacy was the primary driver behind the stock's decline. Eli Lilly’s shares, conversely, saw a rise of up to 4.2% in pre-market trading in the United States, reflecting investor confidence in Zepbound's continued success.

Cagrisema: novo nordisk’s strategy to compete

CagriSema was considered a crucial component of Novo Nordisk’s strategy to compete against emerging, more potent weight loss medications and the eventual patent expirations of their blockbuster drugs, Wegovy and Ozempic. The injection combines semaglutide, the active ingredient in Wegovy and Ozempic, with a compound mimicking the intestinal hormone amilin. The hope was that this dual-action approach would offer superior weight loss results.

Previous setbacks and analyst expectations

The latest disappointing results follow a previous large-scale obesity study that failed to achieve Novo Nordisk’s target weight loss levels. Prior to the release of these findings, analysts, including Colin White of UBS AG, anticipated that the new drug would at least not be worse than Zepbound. The clinical trial comparing CagriSema to tirzepatida began before the earlier disappointing results were published, fueled by initial optimism.

Potential “nokia effect” for denmark?

Denmark’s economy is heavily reliant on Novo Nordisk, and this setback has sparked concerns about a potential